chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Child told mother next morning arm was swollen, itching and hurting. Mother noted rash from shoulder to neck, arm with increased redness and edema. Warm to touch.
Pt received vaccines on 2/14/00, and experienced a generalized seizure on 2/25/00. Pt's mother states "shots caused the seizure".
Worst migraine ever continuing even into 4-16-21 (today), vertigo, chest pain, cough, severe body aches, vison problems
pt recv vax 18JUN98 & 20JUN98 pt devel fatigue;over the period of the next 5-9 days pt also devel enlarged lymph nodes in neck & base of skull;
Rash, swelling, welts, stiffness, knots under the arm, pain up neck & down back. Told her to contact Doctor. Did not report back to us.
Pt called Pharmacy around 5:00 PM and reported nausea, diarrhea, headache, dizziness, and tunnel vision.  These symptoms started about 2 hours after vaccination.  Told pt to contact physician and call 911 for any emergencies.
Patient had the shingles vaccine on Friday 2/12/21.  It was the Shingrix vaccine.  Afterward she felt tired and achy and had slight nausea dizziness chills and a low-grade fever.  8 hours later she was feeling better.  Later that day she developed a couple of spots with a white point and they were itchy over a red base each spot appeared like a vesicle and it was isolated.  Couple days later she developed a cluster of 3-4 vesicles over a red base on the left flank.   Physical exam: Left chest wall noted for cluster of 4 vesicles on the left with an underlying red base.  She also had 2 other red spots with 1 vesicle in the center of each These were on the left but closer to midline in lower thoracic dermatome  Impression Rash after shingles shot.  The reaction looks like shingles flare.  And it seems to be in a dermatomal pattern
Preventricular contractions. Many of them. Every day.  Started feb 26,2021  Stopped around April 17 2021
tested positive for Covid after receiving the shot/had the first dose of the Pfizer Covid-19 vaccine on (19Mar2021) but tested positive to Covid-19 on 25Mar2021; This is a spontaneous report from a contactable consumer (patient). A 63-year-old female patient received first dose of bnt162b2 (BNT162B2, Solution for injection, Batch/lot number and expiry date: not reported) via an unspecified route of administration on 19Mar2021 (at an age of 63 years-old) as dose 1, single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. On 25Mar2021, the patient tested positive for covid. The patient stated that two days before the day of reporting, she took a shot of Damlanivimab at the hospital. Stated that she was supposed to have the second shot on 09Apr2021 and wanted to know since she had some other antibiotic could she take the second shot and clarified that it is for Pfizer Covid vaccine. The patient also wanted to know if its okay to take the second dose after being tested Positive to Covid-19. On 25Mar2021, the patient underwent lab tests and procedures which included sars-cov-2 test: positive. The clinical outcome of the covid-19 was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
This patient received MMR on 08/13/2001, developed joint aches, pain, swelling, on and off itching. "Chest pain" around 08/23/01. Seen 08/31/01 in the ER dept. Had Prednisone and lab work done, CBC, Sed rate, ANA, RF. Also seen 09/07/01, at employee health.
Toddler began to feel warm to the touch in the afternoon of Monday the 14th, temperature was taken at apx 8 pm with a temporal scanner and read 104.  She was given 3.75 mL of childrens Tylenol, which broke the fever and allowed her to sleep. 3-4 times a day, everyday up to and including Thursday the 17th, her temperature spiked to 104 and remained elevated most of the rest of the time.  She was also lethargic and experienced loss of appetite, and was primarily breastfed during those 4 days. She was treated with Tylenol once to twice a day, to help her sleep, and was otherwise treated with sponging room temperature water on her face, neck and torso.  After speaking with advice nurse she was given doses of Tylenol every 4 hours starting Thursday at 5 pm, except while she slept overnight. At the same time the family left for a car trip and toddler was exposed to colder temperatures, which also seemed to help break the fever.  A few times friday she felt warm but her temperature was only slightly elevated.
Patient presented to the ER with recent diagnosis of Covid-19 with complaints of chest pain and shortness of breath. Levophed started, mildly elevated LFTs, initial lactic 2.2, procalcitonin 0.30, troponin negative, CT head no acute intracranial process, CT angiogram chest no evidence pulmonary embolism, subsegmental atelectasis/consolidation of the left and right lower lobe.  Patient treated with cefepime and azithromycin. Patient diagnosed with septic shock secondary to bilateral lower love pneumonia and Covid-19 infection. She completed her course of abx and will continue 5 more days of Doxycycline and Prednisone. Patient discharged to SNU.
Extreme headache.  Behind my eyes hurt so bad.  Even light coming through my eyes when they were closed hurt really bad.  Pain moved into my neck and my joints in my shoulders.
A rash started on the front of my neck the next morning July 31st  after the injection. I had stinging pain, burning sensation and the bumps began draining that day causing the rash to spread on my neck .I returned back to state and I went to see my primary care provider today August 2, 2019. I received the medication Valacyclovir 1 GM and have started it tonight 08/02/2019.
Pulsatile Tinnitus in left ear started 5 days after 2nd dose administered and is ongoing.  Other effects post 2nd dose had resolved before tinnitus began. Other effects experienced were headache, nausea, itching at injection site, diarrhea, fatigue
Pt c/o chest tightness, throat itchiness, continuous coughing, SOB after receiving her first dose of the pfizer vaccine. Epi pen was administered and sent to ED for monitoring.
Body aches, weak joints, legs, whole body pains, weakness and nervousness all over body. Naproxen for the pains.
Patient reported lumps/swelling and pain under left arm ?lymp node area, lasted at least 3 weeks after vaccine
o Triage Presenting Complaint pt received covid vaccine #2 on friday; on saturday morning he developed cold chills, today he developed headache, chest tightness, intermittent sob; denies n-v-d; has taken aleve, pepto, and tums with no change in s/s The patient is a 32 year old Male complaining of multiple complaints. 04/26/2021 00:40 patient,  c/o multiple complaints. Patient states that he received his second Moderna vaccine on Friday, then developed chills, body aches, headache, chest pain. He took Tums, Tylenol without relief. He says that it woke him up in the middle of the night Saturday night with headache and chest pain, but subsided after an hour and he was able to go back to sleep. He states that he had intermittent feelings of sickness all day today until the headache and chest pain worsened this evening and he decided to come in. He denies any radiation of pain, diaphoresis, dizziness, numbness, weakness, vision change, shortness of breath, abdominal pain, or other complaints. He denies any significant PMH at all.
Fever started on 8/24 and continued until 8/25. Starting 8/25 pt experienced SOB and heart racing
pink redness (not bright) and itchiness on the injection site; pink redness (not bright) and itchiness on the injection site; arm hurt on the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (pink redness (not bright) and itchiness on the injection site), VACCINATION SITE ERYTHEMA (pink redness (not bright) and itchiness on the injection site) and VACCINATION SITE PAIN (arm hurt on the injection site) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high and Hypercholesterolaemia. Concomitant products included METFORMIN for an unknown indication.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (pink redness (not bright) and itchiness on the injection site), VACCINATION SITE ERYTHEMA (pink redness (not bright) and itchiness on the injection site) and VACCINATION SITE PAIN (arm hurt on the injection site). At the time of the report, VACCINATION SITE PRURITUS (pink redness (not bright) and itchiness on the injection site), VACCINATION SITE ERYTHEMA (pink redness (not bright) and itchiness on the injection site) and VACCINATION SITE PAIN (arm hurt on the injection site) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication included blood pressure medication and cholesterol medication. Treatment medication was not reported.; Sender's Comments: Based on the current available information which shows a temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded. The reported events are consistent with the product known safety profile.
Information has been received from a registered nurse concerning multiple unspecified patients of unknown age and gender. The patients' medical histories, concurrent conditions and concomitant therapies were not provided. On multiple unspecified dates, the patients were vaccinated with improperly stored GARDASIL 9, lot # L016428, expiration date 30-JUL-2017 (dose and route unspecified), which was exposed to temperature excursion 48.5 Fahrenheit degree (F) for 2 hours. It was not because of a data logger. The vaccine previous temperature excursion was reported as 50.28 F for 7 hours. No adverse effect was reported. Additional information has been requested.
Information has been received from a Licensed Practical Nurse referring to unspecified amount of patients of unknown age and gender. There was no concurrent condition or medical history reported. On unknown dates the patients were vaccinated with improperly stored RECOMBIVAX HB (lot # L029631, expiration date 14-AUG-2017) (dosage, strength and route unknown) (temperature fridge 0.1 degree Centigrade, time frame: 2 hours and 59 minutes). No adverse effect was reported. This is one of several reports received from the same reporter. Additional information is not expected as the reporter did not wish further contact.
This spontaneous case was reported by a consumer and describes the occurrence of FEELING HOT (arm hot to touch), MYALGIA (muscle pain) and INJECTION SITE SWELLING (mark at injection site size of a fist) in a 53-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     Concurrent medical conditions included Allergy (no medical history provided).    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FEELING HOT (arm hot to touch), MYALGIA (muscle pain) and INJECTION SITE SWELLING (mark at injection site size of a fist). At the time of the report, FEELING HOT (arm hot to touch), MYALGIA (muscle pain) and INJECTION SITE SWELLING (mark at injection site size of a fist) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       patient is taking blood pressure medication as concomitant no treatment taken
This spontaneous report was received from a pharmacist referring to a 66 year old female patient with hypertension. On 13-DEC-2016, the patient was vaccinated with a dose of ZOSTAVAX, (lot # M035147, expiry date 25-OCT-2017) in the left arm for prevention of shingles. On the same day the patient was also vaccinated with a dose of BOOSTRIX also in the left arm and with a dose of a 3rd unspecified vaccine at unspecified location of her body. At the time of the vaccination the patient was taken losartan (manufacturer unknown) 50 mg daily. On an unknown date, in December 2016, shortly after received the vaccines, the patient began to experience muscle pain, and stiffness that started from her left shoulder down to her lower arm. The pharmacist reported that after a month the patient had reported that she was still experiencing the same symptoms and then on 27-MAR-2017 the patient went into the pharmacy and reported that she had not gotten better, even after taking medication with cyclobenzaprine and tramadol (unspecified dose and frequency for both products), going to physician therapy and unspecified referrals. The patient stated that she had not experienced anything like that before. The outcome of musculoskeletal stiffness, myalgia and injected limb mobility decreased was reported as not recovered/not resolved. The pharmacist stated that this did affect the patient's ability to perform daily tasks and was very bothersome for her. Additional information has been requested.
Pt given vaccine and 3 minutes later, patient complained of not being able to breath. Epineprine 0.5mg SQ and Benadryl 50 mg IM given
vision issue with one eyes/eyes not being synchronized/one is not performing as well as the other; some elevated heart rate; Having adverse events to the vaccine; it is getting worse; Prolonged headaches; This spontaneous case was reported by a consumer and describes the occurrence of VISUAL IMPAIRMENT (vision issue with one eyes/eyes not being synchronized/one is not performing as well as the other), HEART RATE INCREASED (some elevated heart rate), VACCINATION COMPLICATION (Having adverse events to the vaccine), CONDITION AGGRAVATED (it is getting worse) and HEADACHE (Prolonged headaches) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19 (had COVID  a year ago).   In May 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In May 2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VISUAL IMPAIRMENT (vision issue with one eyes/eyes not being synchronized/one is not performing as well as the other), HEART RATE INCREASED (some elevated heart rate), VACCINATION COMPLICATION (Having adverse events to the vaccine), CONDITION AGGRAVATED (it is getting worse) and HEADACHE (Prolonged headaches). The patient was treated with PREDNISONE at an unspecified dose and frequency; LOTEPREDNOL ETABONATE (LOTEMAX) (ophthalmic) at an unspecified dose and frequency and PROMETHAZINE at an unspecified dose and frequency. At the time of the report, VISUAL IMPAIRMENT (vision issue with one eyes/eyes not being synchronized/one is not performing as well as the other), HEART RATE INCREASED (some elevated heart rate), VACCINATION COMPLICATION (Having adverse events to the vaccine), CONDITION AGGRAVATED (it is getting worse) and HEADACHE (Prolonged headaches) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Heart rate: 90 (High) elevated heart rate of 90 (as opposed to a resting heart rate of 60).         Concomitant medication was not provided.  The patient received both doses of the vaccine around mid-May and late May. The patient got the second vaccine, delayed by 1 to 2 weeks. The condition have aggravated for the last 3 months. The patient was previously not on any medications.  The patient have seen a cardiologist, neurologist and ophthalmologist. There has not been any confirmed diagnosis of the issue. The ophthalmologist had seen that in many cases, it could be a result of the virus or vaccine, an inflammation of the eye and the brain.
Patient experienced a bad reaction; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNISATION REACTION (Patient experienced a bad reaction) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunisation.     No Medical History information was reported.    In 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced IMMUNISATION REACTION (Patient experienced a bad reaction). At the time of the report, IMMUNISATION REACTION (Patient experienced a bad reaction) outcome was unknown.            Concomitant product use was not provided by the reporter.  Patient experienced adverse reaction with booster dose. It was reported the patient experienced a bad reaction and that patient would not be getting another dose.  Treatment information was not provided.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient. A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administration date 20Nov2021 (Batch/Lot number: unknown) as dose 3 (booster), single, administration date 09Apr2021 (Batch/Lot number: unknown) as dose 2, single and administration date 17Mar2021 (Batch/Lot number: unknown) as dose 1, single for Covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HEPATITIS C (medically significant), outcome "unknown", described as "Hep C"; HEPATIC ENZYME INCREASED (non-serious) with onset 2021, outcome "unknown", described as "No history of elevated liver levels enzymes etc. until after two vaccinations and the booster". The patient underwent the following laboratory tests and procedures: hepatic enzyme: (2021) elevated. Therapeutic measures were taken as a result of hepatitis C. Clinical course: The patient asked Where can find copies of liver impact studies related to the Pfizer Vaccine. The patient do not fall into any of the categories related to risk for Hep C infection. Any guidance you can provide as to current clinical trials or studies would be appreciated. The lot number for bnt162b2 was not provided and will be requested during follow up.
Tiredness; Nausea; Headaches; Fever; feeling very sick; This non-serious case was reported by a consumer via call center representative and described the occurrence of tiredness in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 18-SEP-2023, the patient received the 1st dose of Shingrix. In SEP-2023, an unknown time after receiving Shingrix, the patient experienced tiredness (Verbatim: Tiredness), nausea (Verbatim: Nausea), headache (Verbatim: Headaches), fever (Verbatim: Fever) and sickness (Verbatim: feeling very sick).  The outcome of the tiredness and fever were not resolved and the outcome of the nausea, headache and sickness were unknown.   It was unknown if the reporter considered the tiredness, nausea, headache, fever and sickness to be related to Shingrix.     It was unknown if the company considered the tiredness, nausea, headache, fever and sickness to be related to Shingrix.   Additional Information: GSK Receipt Date: 21-SEP-2023 The reporter stated that she received Shingrix first dose on Monday and that night started with fever, headaches and nauseas, feeling very sick Monday and Tuesday. On the day of reporting, still had low fever and tiredness. Treating physician was not aware. The reporter did not consent to follow up.
Rash around injection site.  Tongue swelling starting 1 day after injection and lasting for 3 days
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. No information regarding the patient's medical history or concurrent conditions was provided. On 19-JUN-2017, the patient was vaccinated with an expired dose of M-M-R II injection (lot# L020188, expiry date 03-JUN-2017; exact dose, route of administration and albumin status were not reported), reconstituted with DILUENT MRK. No adverse effects were reported. There was no product quality complaint involved. Additional information has been requested.
This is an instance of breakthrough COVID-19 disease after which death occurred.   The individual was vaccinated with the Moderna product on 01/21/2021 and 02/18/2021.   The individual did not have a known specific symptom onset date but tested positive via PCR test on 08/30/2021 at the nursing home at which they were a resident. They died on 09/01/2021.
Chills that have lasted for 1 week- still happening Numb fingers on left hand- happened immediately and lasted 4 days Numb left calf and heel- happened 16 hours after vaccine dose and still numb 1 week later
Co-worker called to state that child was diagnosed with whooping cough. Both mother and child placed on Zithromax and a nasal swab was done of child on 08/15/2012.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 53-year-old female patient (not pregnant) received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 14Sep2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 52 years, in right arm for covid-19 immunisation; covid-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. No Known allergies. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19. Patient used Paxlovid from 15Sep2023 to 19Sep2023 as treatment.  The information on the batch/lot number for bnt162b2, bnt162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Information has been received from a RN concerning a 8 y/o 8 who on 15Jun98 was vaccinated with a dose of varicella virus vaccine live. On 24Jul2003, 2 weeks after exposure to a 4 year old child who on 11Jul2003 was diagnosed with shingles (also reported as a child with chicken pox and a child who had chicken pox illness in April 2000), the pt was seen at the physician's office and was found to have a mild case of chicken pox. No treatment was required.  No product quality complaint was involved. It was also reported that 3 other children were vaccinated with a dose of varicella virus vaccine live and developed a mild case of chicken pox. Additional information has been requested.
Immediately after giving the vaccine,  noticed the injection site becoming red and swollen. We gave her 12.5mg of benadryl and an ice pack. We made the patient stay for 30 minutes of observation where at the end of the time, the swelling and redness had gone down
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose 12/22/21,pfizer,Lot#EK9231 2nd dose: 01/11/21,Pfizer,Lot# EL3248 Diagnosed covid positive:07/13/21 Exposure:Community Symptoms: All symptoms.(fever, headache,nausea, loss of smell, body aches, sore throat)